2016
DOI: 10.1097/hjh.0000000000000845
|View full text |Cite
|
Sign up to set email alerts
|

AT1-receptor blockade, but not renin inhibition, reduces aneurysm growth and cardiac failure in fibulin-4 mice

Abstract: Losartan, but not aliskiren or propranolol, improved survival in fibulin-4 mice. This most likely relates to its capacity to improve structure and function of both aorta and heart. The absence of this effect during aliskiren treatment, despite a similar degree of blood pressure reduction and renin-angiotensin system blockade, suggests that it might be because of AT2-receptor stimulation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 14 publications
(8 citation statements)
references
References 56 publications
(68 reference statements)
0
8
0
Order By: Relevance
“…These data show that Smad3 −/− animals experience rapid aneurysmal growth, and concurrent early death. Again, this is in contrast to Fibulin-4 R/R animals that are born with an aneurysm, which shows a slow but progressive growth with age (Te Riet et al, 2016). …”
Section: Resultsmentioning
confidence: 81%
“…These data show that Smad3 −/− animals experience rapid aneurysmal growth, and concurrent early death. Again, this is in contrast to Fibulin-4 R/R animals that are born with an aneurysm, which shows a slow but progressive growth with age (Te Riet et al, 2016). …”
Section: Resultsmentioning
confidence: 81%
“…In view of all these considerations, the failure of TGF-β-neutralizing antibody treatment to suppress p-Smad2/3 and ameliorate disease in LDS mouse models seems more likely to be explained by issues related to bioavailability, as also observed in other TGF-β-related pathologies (76), rather than inferences regarding loss or gain of TGF-β activity in the pathogenesis and treatment of disease (22)(23)(24). While protective therapeutic trials in preclinical models associate with attenuation of biochemical and gene expression signatures indicative of TGF-β signaling (19,48,(52)(53)(54)(55)(56), ambiguity remains as to the relative contribution of TGF-β inhibition to disease amelioration, and the role of TGF-β signaling as a primary driver or a nonspecific late-stage consequence of disease (21,24,46,56,57). Ongoing controversy has also been fueled by the observation that genetic abrogation of TGF-β signaling in VSMCs can result in severe and widespread aortopathy, or exacerbation of vessel wall disruption caused by other insults such as AngII infusion or genetic predisposition for aneurysm (58)(59)(60)(61)(62)(63)(64)(65).…”
Section: Discussionmentioning
confidence: 99%
“…FBLN4 is essential for connective tissue development and elastic fiber formation, and it plays an important role in vascular patterning and collagen biosynthesis 37. Moreover, it is involved in the onset and progression of many diseases, including aortic aneurysms,38,39 cutis laxa,40,41 and osteoarthritis 42. FBLN4 has been observed to be a specific protein partner for mutant p53, and it displays both mutant p53-dependent and -independent oncogenic properties, with implications for both cancer biology and therapeutic intervention.…”
Section: Discussionmentioning
confidence: 99%